Phaseline

Companies › Beijing Gene Key Life Technology

Beijing Gene Key Life Technology: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GKL-006 Injection
iNKT cell therapy (invariant natural killer T cell therapy)
–Phase 2Hepatocellular Carcinoma (HCC); Advanced Pancreatic CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07713290GKL-006 InjectionPhase 1Hepatocellular Carcinoma (HCC)OncologyNov 2026
NCT07777211GKL-006 InjectionPhase 1Advanced Pancreatic CancerOncologyMar 2027
NCT07209813GKL-006 InjectionPhase 2Hepatocellular Carcinoma (HCC)OncologySep 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Hangzhou Converd Abscint NV/SA CNBG-Virogin Biotech (Shanghai) Stella Pharma Dendreon

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.